Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro

References

• Ezzati M, Lopez AD, Rodgers A, et al.; Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347–60
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217–23
   PubMed Web of Science ®Google Scholar
• Reddy KS, Shah B, Varghese C, Ramadoss A. Responding to the threat of chronic diseases in India. Lancet 2005;366:1744–9
   PubMed Web of Science ®Google Scholar
• Gupta R, Joshi P, Mohan V, et al. Epidemiology and causation of coronary heart disease and stroke in India. Heart 2008;94:16–26
   PubMed Web of Science ®Google Scholar
• Havsteen B. Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol 1983;32:1141–8
   PubMed Web of Science ®Google Scholar
• Rice-Evans C, Miller NG, Paganga G. Structure antioxidant activity relationships of flavonoids and phenolic acids. Free Rad Biol Med 1996;20:833–956
   Google Scholar
• Kanaze FI, Bounartzi MI, Georgarakis M, Niopas I. Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. Eur J Clin Nutr 2007;61:472–7
   PubMed Web of Science ®Google Scholar
• Joshipura KJ, Ascherio A, Manson JE, et al. Fruit and vegetable intake in relation to risk of ischemic stroke. JAMA 1999;282:1233–9
   PubMed Web of Science ®Google Scholar
• Raza SS, Khan MM, Ahmad A, et al. Neuroprotective effect of naringenin is mediated through suppression of NF-κB signaling pathway in experimental stroke. Neuroscience 2013;230:157–71
   PubMed Web of Science ®Google Scholar
• Renugadevi J, Milton Prabu S. Cadmium-induced hepatotoxicity in rats and the protective effect of naringenin. Exp Toxicol Pathol 2010;62:171–81
   PubMed Web of Science ®Google Scholar
• Anshu Jaina, Abhishek Yadav, Bozhkov AI, et al. Therapeutic efficacy of silymarin and naringenin in reducing arsenic-induced hepatic damage in young rats. Ecotoxicol Environ Saf 2011;74:607–14
   PubMed Web of Science ®Google Scholar
• Lee CH, Jeong TS, Choi YK, et al. Antiatherogenic effect of citrus flavonoid, naringin and naringenin associated with hepatic ACAT and acrostic VCAM-1 and MCP-1 in high cholesterol fed rabbits. Biochem Biophys Res Commun 2001;284:681–8
   PubMed Web of Science ®Google Scholar
• Badary OA, Maksoud SA, Ahmed WA, Owieda GH. Naringenin attenuates cisplatin nephrotoxicity in rats. Life Sciences 2005;76:2125–35
   PubMed Web of Science ®Google Scholar
• Ting S, Yeh HS, Lien TF. Effects of supplemental levels of hesperetin and naringenin on egg quality, serum traits and antioxidant activity of laying hens. Anim Feed Sci Tech 2011;163:59–66
   Web of Science ®Google Scholar
• Gao K, Henning SM, Niu Y, et al. The citrus flavonoid naringenin stimulates DNA repair in prostate cancer cells. J Nutr Biochem 2006;17:89–95
   PubMed Web of Science ®Google Scholar
• Jeon SM, Kim HK, Kim H-J, et al. Hypocholesterolemic and antioxidative effects of naringenin and its two metabolites in high-cholesterol fed rats. Transl Res 2007;149:15–21
   PubMed Web of Science ®Google Scholar
• Fauci SA, Braunwald E, Kasper DL, et al. Harrison’s principles of internal medicine. 17th ed. New York: Mc Graw Hill; 2008:1523
   Google Scholar
• Dipiro JT. Pharmacotherapy: a pathophysiologic approach. 7th ed. New York: Mc Graw Hill; 2008:257
   Google Scholar
• Acartfirk F, Sencan A. Investigation of the effect of different adjuvants on felodipine release kinetics from sustained release monolithic films. Int J Pharm 1996;131:183–9
   Google Scholar
• Challa VR, Babu PR, Challa SR, et al. Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models. Drug Dev Ind Pharm 2013;39:865–72
   PubMed Web of Science ®Google Scholar
• Barthe L, Woodley J, Houin G. Gastrointestinal absorption of drugs: methods and studies. Fundam Clin Pharmacol 1999;13:154–68
   PubMed Web of Science ®Google Scholar
• Babu PR, Babu KN, Peter PL, et al. Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models. Drug Dev Ind Pharm 2013;39:873–9
   PubMed Web of Science ®Google Scholar
• Capraro J, Clemente A, Rubio LA, et al. Assessment of the lupin seed glucose-lowering protein intestinal absorption by using in vitro and ex vivo models. Food Chemistry 2011;125:1279–83
   Web of Science ®Google Scholar
• Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450 – mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT – 538) in human liver microsomes. J Pharmacol Exp Ther 1996;277:423–31
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Bedynek PS, Walker A, et al. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics. II. Ritonavir effects on CYP3A and Pglycoprotein activities. Clin Pharmacol Ther 2008;84:506–12
   PubMed Web of Science ®Google Scholar
• Li F, Lu J, Ma X. CPY3A4-mediated lopinavir bioactivation and its inhibition by ritonavir. Drug Metab Dispos 2012;40:18–24
   PubMed Web of Science ®Google Scholar
• Kallem RR, Ramesh M, Seshagirirao JVLN. Validated LC-ESI-MS/MS method for simultaneous quantitation of felodipine and metoprolol in rat plasma: application to a pharmacokinetic study in rats. Biomed Chromatogr 2013;27:784–91
   PubMed Web of Science ®Google Scholar
• Robinson JR. Semi-solid formulations for oral drug delivery. Bull Tech Gattefosse 1996;89:11–13
   Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010;9:215–36
   PubMed Web of Science ®Google Scholar
• Wu C-Y, Benet LZ. Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and GG918. Drug Metab Dispos 2003;31:1292–5
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Walker A, Hoffer C, Sheffels P. Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination. J Clin Pharmacol 2005;45:79–88
   PubMed Web of Science ®Google Scholar
• Lin JH. Drug–drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 2003;55:53–81
   PubMed Web of Science ®Google Scholar
• Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinogen 1995;13:129–34
   PubMed Web of Science ®Google Scholar
• Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately upregulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996;49:311–18
   PubMed Web of Science ®Google Scholar
• Fenner KS, Troutman MD, Kempshall S, et al. Drug–drug interactions mediated through P-glycoprotein: clinical relevance and in vitro–in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 2009;85:173–81
   PubMed Web of Science ®Google Scholar
• Madsen JK, Jensen JD, Jensen LW. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. Eur J Clin Pharmacol 1996;50:203–8
   PubMed Web of Science ®Google Scholar
• Hansten PD, Horn JR. Cytochrome P450 enzymes and drug interactions, table of cytochrome P450 substrates, inhibitors, inducers and P-glycoprotein, with footnotes. In: The top 100 drug interactions – a guide to patient management. Freeland WA: H & H Publications; 2008:142–57
   Google Scholar
• Wang YH, Chao PD, Hsiu SL, et al. Lethal quercetin--digoxin interaction in pigs. Life Sci 2004;74:1191–7
   PubMed Web of Science ®Google Scholar
• Laurian V, Maria N, Adino P, et al. Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers. A prospective pilot study. Curr Therap Res 2010;71:360–8
   PubMed Web of Science ®Google Scholar
• Neerati P, Gade J. Influence of atorvastatin on the pharmacokinetics and pharmacodynamics of glyburide in normal and diabetic rats. Eur J Pharm Sci 2011;42:285–9
   PubMed Web of Science ®Google Scholar
• Yamreudeewong W, DeBisschop M, Martin LG. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf 2003;26:421–38
   PubMed Web of Science ®Google Scholar
• Henderson L, Yue QY, Bergquist C. St John’s wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002;54:349–56
   PubMed Web of Science ®Google Scholar
• Bansal T, Jaggi M, Khar RK, Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharmaceut Sci 2009;12:46–78
   PubMed Web of Science ®Google Scholar
• Collett A, Tanianis-Hughes J, Carlson GL, et al. Comparison of P-glycoprotein-mediated drug--digoxin interactions in Caco-2 with human and rodent intestine: relevance to in vivo prediction. Eur J Pharm Sci 2005;26:386–93
   PubMed Web of Science ®Google Scholar